RegCell

Restoring self tolerance to the immune system

Emeryville, United States · $45.8M raised

Employees
11–50
Business Model
B2B
Total Funding
$45.8M
Last Round
$37.3M GrantMar 2025
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

RegCell is a clinical-stage cell therapy company headquartered in Emeryville, California, developing regulatory T cell (Treg) therapies to restore immune tolerance in patients with autoimmune diseases such as rheumatoid arthritis, Type 1 diabetes, multiple sclerosis, and lupus. Founded on the Nobel Prize-winning discoveries of Dr. Shimon Sakaguchi — who first characterized Tregs and their role in preventing autoimmunity — RegCell's platform uses epigenetically reprogrammed induced Tregs to deliver antigen-specific immune tolerance rather than broad immunosuppression. The company completed its U.S. headquarters transition in March 2025 following a $45.8M seed financing co-led by Fast Track Initiative and UTEC, and has partnered with Kincell Bio for cell therapy manufacturing toward clinical trials.

Summary

RegCell is a Biotech company based in Emeryville, United States. It has raised $45.8M in total across 2 rounds, most recently a $37.3M Grant round in Mar 2025. Investors include Japanese Agency for Medical Research and Development (AMED), Fast Track Initiative, and UTEC - The University.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

GrantMar 2025
$37.3M

Sign up to see all 2 events

Funding: Grant through Seed. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

RegCell on Indexed.vc
<a href="https://indexed.vc/companies/regcell"><img src="https://indexed.vc/api/badge/company/regcell" alt="RegCell on Indexed.vc" width="260" height="76" /></a>